Age | 64.7 (11) |
Women, n (%) | 150 (75) |
European, n (%) | 161 (80) |
Body Mass Index, Kg/m2 | 27.8 (5.3) |
Disease duration, years | 15.9 (13.6) |
Disease type, n (%) | Â |
 Rheumatoid factor positive | 162 (81) |
 Anti-CCP antibodies positive | 105 (76) |
 Seronegative | 26 (13) |
RA medications, n (%) | Â |
 DMARD monotherapy | 71 (35) |
 Combination DMARD therapy (≥2 DMARDs) | 104 (52) |
 Biologics | 33 (16) |
 Prednisone | 74 (37) |
Other medications, n (%) | Â |
 Opiates | 18 (9) |
 Anti-platelets | 44 (22) |
 Anti-coagulants | 11 (6) |
 Anti-hypertensive | 91 (45) |
 Hypoglycaemias | 16 (8) |
 Psychotropics | 37 (18) |
Number of medications | 4.1 (2.0) |
Number of co-morbidities | 1.2 (1) |
Co-morbid conditions, n (%) | Â |
 Hypertension | 73 (36) |
 Other vascular disease | 29 (14) |
 Diabetes Mellitus | 18 (9) |
 Parkinson’s disease | 2 (1) |
 Osteoporosis | 39 (19) |
 Depression or bipolar disorder | 16 (8) |
Patient self-reported pain (VAS 0–100), mm | 39 (27) |
Patient global (VAS 0–100), mm | 36 (26) |
Tender joint count (total) | 11 (12) |
Swollen joint count (total) | 5 (7) |
DAS28-CRP score | 3.38 (1.26) |
Short FES-I score (7–28) | 12 (5) |
HAQ-II score | 0.89 (0.62) |
Wears glasses or contact lenses, n (%) | 181 (90) |
Uses assistive device, n (%) | 57 (28) |